BIOLASE, Inc. (OTCQB:BIOL) Q2 2020 Earnings Conference Call August 13, 2020 4:30 PM ET Company Participants Todd Kehrli - The EVC Group Todd Norbe - Chief Executive Officer John Beaver - Chief Financial Officer Conference Call Participants Kyle Bauser - Colliers Securities Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE 2020 Second Quarter Financial Results Conference Call. Today's conference is being recorded. And at this time, I would like to tur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 BIOLASE, INC. (Exact name of registrant as specified in its charter) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 Delaware 87-0442441 (State or other jurisdiction of incorporatio ...

BIOLASE Inc (OTCQB:BIOL) Q1 2020 Results Conference Call May 7, 2020 4:30 PM ET Company Participants Todd Kehrli - The EVC Group Todd Norbe - Chief Executive Officer John Beaver - Chief Financial Officer Conference Call Participants Bruce Jackson - The Benchmark Company Kyle Bauser - Dougherty & Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE 2020 First Quarter Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 BIOLASE, INC. (Exact name of registrant as specified in its charter) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36385 Delaware 87-0442441 (State or other jurisdiction of incorporati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36385 BIOLASE, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 87-0442441 (State or Other Jurisdiction of Incorpor ...

BIOLASE, Inc. (OTCQB:BIOL) Q4 2019 Earnings Conference Call March 26, 2020 4:30 PM ET Company Participants Todd Kehrli - EVC Group Todd Norbe - President and Chief Executive Officer John Beaver - Executive Vice President and Chief Financial Officer Conference Call Participants Kyle Bauser - Dougherty Bruce Jackson - The Benchmark Company Ed Woo - Ascendiant Capital Operator Good day and welcome to the BIOLASE 2019 Fourth Quarter and Year End Financial Results Conference Call. Today's conference is being re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock at par value $0.001 per share BIOL The NASDAQ Stock Market LLC (NASDAQ Capital Market) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 1 ...

BIOLASE, Inc. (OTCQB:BIOL) Q3 2019 Earnings Conference Call November 6, 2019 4:30 PM ET Company Participants Todd Kehrli - EVC Group Todd Norbe - President and CEO John Beaver - EVP and CFO Conference Call Participants Kyle Bauser - Dougherty Bruce Jackson - The Benchmark Company Ed Woo - Ascendiant Capital Lisa Springer - Singular Research Operator Good day everyone, and welcome to the BIOLASE 2019 Third Quarter Financial Results Conference Call. Today's call is being recorded. At this time, I would like t ...

| --- | --- | --- | --- | |--------------------|--------------------------------|-----------------------|-------| | | | | | | | | | | | | | INVESTOR PRESENTATION | | | Waterlase Express™ | NASDAQ CM: BIOL September 2019 | | | Safe Harbor Statement Statements made in this presentation and during discussions with BIOLASE representative's that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements its representatives make c ...

Financial Data and Key Metrics Changes - Total worldwide revenue for Q2 2019 was $8.7 million, a 29% decrease compared to $12.2 million in Q2 2018 [26] - U.S. revenue decreased 18% year-over-year, with Waterlase sales impacted by a 30% decline due to vacant sales territories [26][27] - Gross margin for Q2 2019 was 39%, up 370 basis points from 35% in Q2 2018, reflecting a favorable product mix and better pricing discipline [30] - Operating loss for Q2 2019 was $3.3 million, a decrease of 29% year-over-year from $4.7 million in Q2 2018 [32] - Net loss for Q2 2019 was $3.9 million or $0.18 loss per share, compared to a net loss of $4.9 million or $0.24 loss per share in the prior year [32] Business Line Data and Key Metrics Changes - Consumables and other revenue in the U.S. increased 2% year-over-year, indicating increased utilization of lasers [28] - International revenue for Q2 2019 was $2 million, down about $2 million compared to the prior year, primarily due to pricing discipline efforts [28] Market Data and Key Metrics Changes - Revenue from the Model Market Initiative increased 31% compared to last year's second quarter, demonstrating growing interest in the technology [17] - The pediatric market in LA, Orange County, and Dallas showed success with new sales strategies, leading to higher customer acquisition rates [18] Company Strategy and Development Direction - The company is transitioning from an R&D-centric model to a disciplined commercial organization, focusing on rebuilding the sales team and improving sales processes [13][14] - Strategic decisions included exiting the unprofitable imaging business and enhancing pricing discipline with international distributors [15][16] - The company aims to achieve EBITDA positive status in Q4 2019 through cost reduction initiatives and improved operational efficiencies [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term growth prospects despite short-term revenue impacts from strategic changes [11][23] - The focus remains on expanding the adoption of all-tissue lasers and enhancing the commercial engine to drive growth [19][23] Other Important Information - The McGuire study aims to create a new standard of care for specialists, with interim data expected by the end of 2019 [22] - The company is actively pursuing working capital initiatives, particularly in managing international receivables and inventory [49][51] Q&A Session Summary Question: Can you break out the sales by bucket and laser, imaging, consumables, services? - Consumables were slightly up, while lasers were significantly down due to strategic decisions impacting sales [38] Question: What is the plan to recover the one-third of territories that were vacant in the quarter? - The company is actively searching for new hires and implementing a rigorous assessment process to find suitable candidates [40] Question: Can you provide insight into the DSO market and its potential? - The DSO market is the largest and fastest-growing segment in the dental industry, with significant opportunities for scaling technology adoption [42] Question: Where do you see the greatest opportunity for margin expansion? - Opportunities exist in manufacturing cost reductions and increased revenue in Q4, which is typically the best quarter [45] Question: What are some of the working capital initiatives underway? - The company is focusing on improving international DSO and managing inventory while exploring additional capital raise alternatives [48][52] Question: Can you elaborate on the sales force initiatives? - The company is enhancing its hiring and training processes to ensure the right talent is brought on board [53][56] Question: When might conversations with DSOs lead to expanded relationships? - The company is actively working on generating data to demonstrate the return on investment for DSOs, which is crucial for expanding relationships [57]